Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Kiniksa Pharmaceuticals Ltd (KNSA)

Kiniksa Pharmaceuticals Ltd (KNSA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 839,085
  • Shares Outstanding, K 54,878
  • Annual Sales, $ 0 K
  • Annual Income, $ -103,230 K
  • 60-Month Beta -0.95
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.38

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.57
  • Number of Estimates 2
  • High Estimate -0.54
  • Low Estimate -0.60
  • Prior Year -0.88
  • Growth Rate Est. (year over year) +35.23%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.70 +42.01%
on 12/31/19
15.98 -4.94%
on 01/16/20
+2.91 (+23.74%)
since 12/23/19
3-Month
5.74 +164.72%
on 10/25/19
15.98 -4.94%
on 01/16/20
+9.10 (+149.51%)
since 10/23/19
52-Week
5.01 +203.29%
on 10/17/19
23.04 -34.05%
on 01/25/19
-8.09 (-34.73%)
since 01/23/19

Most Recent Stories

More News
Kiniksa Announces Pipeline Progress and Reiterates 2020 Clinical Data Readouts

- Enrollment target achieved for rilonacept Phase 3 trial in recurrent pericarditis; top-line data expected in 2H 2020 -

KNSA : 15.08 (-1.37%)
The Zacks Analyst Blog Highlights: Amarin, Amgen, Gilead Sciences, Biogen and Kiniksa Pharmaceuticals

The Zacks Analyst Blog Highlights: Amarin, Amgen, Gilead Sciences, Biogen and Kiniksa Pharmaceuticals

AMGN : 234.29 (-1.04%)
BIIB : 284.01 (-1.42%)
GILD : 63.20 (-0.36%)
AMRN : 20.65 (-0.82%)
KNSA : 15.08 (-1.37%)
Biotech Stock Roundup: AMRN Stock Up, Pipeline Updates from GILD, BIIB, AMGN & More

The biotech sector was in focus this week with pipeline and regulatory updates from quite a few players.

AMGN : 234.29 (-1.04%)
BIIB : 284.01 (-1.42%)
AMRN : 20.65 (-0.82%)
ALXN : 109.02 (-2.14%)
GILD : 63.20 (-0.36%)
KNSA : 15.08 (-1.37%)
Gilead Teams Up With Kiniksa, Submits BLA for CAR T Therapy

Gilead (GILD) collaborates with Kiniksa for a combination study and submits BLA for CAR T therapy candidate.

NVS : 94.64 (-0.60%)
GSK : 47.70 (-0.19%)
GILD : 63.20 (-0.36%)
KNSA : 15.08 (-1.37%)
Kite and Kiniksa Pharmaceuticals Announce Clinical Collaboration Evaluating Investigational Combination of Yescarta(R) and Mavrilimumab in Relapsed or Refractory Large B-Cell Lymphoma

Kite, a Gilead Company (Nasdaq: GILD), and Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) ("Kiniksa") announced today that the companies have entered into a clinical collaboration to conduct a Phase 2, multicenter...

GILD : 63.20 (-0.36%)
KNSA : 15.08 (-1.37%)
Kiniksa Pharmaceuticals to Present at 38th Annual J.P. Morgan Healthcare Conference

Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that Sanj K. Patel, Chief Executive Officer and Chairman of the Board of Kiniksa, will present at the 38 Annual J.P. Morgan Healthcare Conference...

JPM : 135.12 (-1.14%)
KNSA : 15.08 (-1.37%)
Company News For Nov 21, 2019

Companies in the news are: URBN, KNSA, ACB, ENDP

ENDP : 6.48 (+2.53%)
URBN : 26.38 (-0.26%)
KNSA : 15.08 (-1.37%)
ACB : 2.08 (+1.96%)
Cancer Drugs and New Therapies for Dangerous Brain Tumors Advancinghl2Financialnewsmedia.com News Commentary

The U.S. Food and Drug Administration (FDA) as part of its mission, is responsible for protecting the public health by assuring the safety, effectiveness, and security of human drugs, vaccines and medical...

CNSP : 4.45 (+1.37%)
QBIO : 2.1700 (-1.36%)
KNSA : 15.08 (-1.37%)
ARAV : 10.72 (-1.11%)
BMY : 66.72 (-1.05%)
Kiniksa Pharmaceuticals to Present at the 2nd Annual Evercore ISI HealthCONx Conference

Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 2 Annual Evercore ISI HealthCONx Conference on Wednesday, December 4, 2019 at 3:30 p.m. Eastern Time at the Four...

KNSA : 15.08 (-1.37%)
Kiniksa Announces Breakthrough Therapy Designation for Rilonacept for the Treatment of Recurrent Pericarditis

Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) ("Kiniksa"), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant...

KNSA : 15.08 (-1.37%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Average short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade KNSA with:

Business Summary

Kiniksa Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa Pharmaceuticals Ltd. is based in Massachusetts,...

See More

Key Turning Points

2nd Resistance Point 16.03
1st Resistance Point 15.66
Last Price 15.08
1st Support Level 15.06
2nd Support Level 14.83

See More

52-Week High 23.04
Fibonacci 61.8% 16.15
Last Price 15.08
Fibonacci 50% 14.03
Fibonacci 38.2% 11.90
52-Week Low 5.01

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar